A Phase 4 interventional study of Dextromethorphan and Placebo in Common Cold and Infections, Upper Respiratory Tract, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-09-20.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Common Cold with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Common Cold · United States.
Among the 47 studies in Common Cold with a site in United States, this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2010, is one of 3 in phase 4, and was the 20th registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →7 of the 47 studies in Common Cold with a site in United States are open now. Recruiting first, the newest first:
Colorado State University · Sites in United States
Ages 18–40 · Healthy volunteers
Quantec Ltd · Sites in United States
Ages 60+ · Healthy volunteers
Center For Interventional Pain and Spine · Sites in United States
Ages 18+ · Healthy volunteers
Indiana University · Sites in United States
Ages 18–40 · Healthy volunteers
Children's National Research Institute · Sites in United States
Ages 6–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is close to the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 228 across the 40 interventional studies, 121 across the 6 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Common Cold — fewer than ten, so there is no comparison to draw.
3 of the studies in Common Cold with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05822141Indiana UniversityOmega-3 Fatty Acids as Regulators of Brown Adipose Tissue During Cold Exposure | 2026-12 |
| NCT07297823Colorado State UniversitySex Differences in Cold-Induced Changes in Maximal Fat Oxidation | 2026-12-31 |
| NCT07706595University of California, San DiegoA Randomized Controlled Trial Comparing Posterior Nasal Nerve Ablation Procedures for Chronic Rhinitis | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Common Cold with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.
In light of protocol changes required due to methodological and operational issues, including background noise in cough recordings which could impact data interpretation, the study has been terminated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female healthy children ages 6 to under 12 years who are symptomatic with a cough due to a cold or acute URTI characterized by:
General good health, aside from a common cold, and has no to the study or rescue medication
Exclusion Criteria:
History of cardiovascular, pulmonary, hepatic, renal, neurological, hematological, , psychiatric, metabolic, gastro-intestinal or endocrine disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dextromethorphan
Drug: Placebo
A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
A single 10 mL dose of matching placebo syrup
Total Cough Count
Total cough count was done by trained assessors using continuous digital video and audio recordings.
Time frame: Up to 6 hours post-dose
Change From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period
Perceived verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline over the 6-hour post-dosing period calculated as the average of change from baseline \[that is (i.e.) baseline value minus the post baseline value\] measurements of Hour 1 to Hour 6, thus the change from baseline ranged from -4 to 4; higher score indicated a better improvement.
Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours post-dose
Change From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6
Verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline values were derived by subtracting each post baseline value from the baseline value, and ranged from -4 to 4; higher score indicated a better improvement.
Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours
Change From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period
Perceived numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = did not cough at all and 10 = cough a lot. The change from baseline for the 6-hour post-dosing period was calculated as the average of change from baseline (i.e. baseline value minus the post baseline value) measurements of Hour 1 to Hour 6, thus the change from baseline values ranged from -10 to 10; higher score indicated a better improvement.
Time frame: Baseline, 1, 2, 3, 4, 5, 6 hour post-dose
Change From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6
Numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", wherein 0 = did not cough at all and 10 = cough a lot. The change from baseline was derived by subtracting the post baseline value from the baseline value and ranged from -10 to 10; higher score indicated a better improvement.
Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours
Participants' Global Assessment of Cough: Cough Severity
Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question " How much have you coughed in the past 6 hours?" where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot.
Time frame: Within 5 minutes after Hour 6
Participants' Global Assessment of Cough: Relief From Cough
Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question "From when you woke up this morning until now, how much better is your cough?" where 0 = not at all better, 1 = a tiny bit better, 2 = a little better, 3 = better and 4 = a lot better.
Time frame: Within 5 minutes after Hour 6
| Milestone | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Started | 55 | 52 |
| Completed | 52 | 45 |
| Not completed | 3 | 7 |
| Withdrew: Protocol violation | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Total cough count was done by trained assessors using continuous digital video and audio recordings.
| Cough counts | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Total Cough Count | 238.7 ± 252.3 | 190.9 ± 190.6 |
Perceived verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline over the 6-hour post-dosing period calculated as the average of change from baseline \[that is (i.e.) baseline value minus the post baseline value\] measurements of Hour 1 to Hour 6, thus the change from baseline ranged from -4 to 4; higher score indicated a better improvement.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Baseline | 3.0 ± 0.9 | 2.9 ± 0.9 |
| Change for 6 hour post-dose period | 1.3 ± 1.1 | 1.1 ± 1.1 |
Verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline values were derived by subtracting each post baseline value from the baseline value, and ranged from -4 to 4; higher score indicated a better improvement.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Change at 1 hour | 1.0 ± 1.2 | 0.9 ± 1.2 |
| Change at 2 hours | 1.2 ± 1.2 | 0.9 ± 1.4 |
| Change at 3 hours | 1.3 ± 1.2 | 0.9 ± 1.4 |
| Change at 4 hours | 1.4 ± 1.3 | 1.1 ± 1.4 |
| Change at 5 hours | 1.7 ± 1.3 | 1.2 ± 1.4 |
| Change at 6 hours | 1.5 ± 1.4 | 1.2 ± 1.4 |
Perceived numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = did not cough at all and 10 = cough a lot. The change from baseline for the 6-hour post-dosing period was calculated as the average of change from baseline (i.e. baseline value minus the post baseline value) measurements of Hour 1 to Hour 6, thus the change from baseline values ranged from -10 to 10; higher score indicated a better improvement.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Baseline | 6.8 ± 2.2 | 7.0 ± 2.3 |
| Change for 6 hour post-dose period | 2.8 ± 2.5 | 2.5 ± 3.1 |
Numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", wherein 0 = did not cough at all and 10 = cough a lot. The change from baseline was derived by subtracting the post baseline value from the baseline value and ranged from -10 to 10; higher score indicated a better improvement.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Change at 1 hour | 2.0 ± 2.9 | 2.0 ± 2.8 |
| Change at 2 hours | 2.5 ± 2.6 | 2.1 ± 3.5 |
| Change at 3 hours | 2.7 ± 2.7 | 2.3 ± 3.5 |
| Change at 4 hours | 2.9 ± 2.8 | 2.5 ± 3.6 |
| Change at 5 hours | 3.6 ± 2.8 | 3.0 ± 3.2 |
| Change at 6 hours | 3.4 ± 3.3 | 2.8 ± 3.8 |
Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question " How much have you coughed in the past 6 hours?" where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Participants' Global Assessment of Cough: Cough Severity | 3.1 ± 0.9 | 3.0 ± 1.3 |
Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question "From when you woke up this morning until now, how much better is your cough?" where 0 = not at all better, 1 = a tiny bit better, 2 = a little better, 3 = better and 4 = a lot better.
| Units on a scale | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| Participants' Global Assessment of Cough: Relief From Cough | 2.9 ± 1.0 | 2.7 ± 1.3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/55 (0%) | 4/55 (7.3%) |
| Dextromethorphan Hydrobromide | — | 0/52 (0%) | 6/52 (11.5%) |
| Event | Placebo | Dextromethorphan Hydrobromide |
|---|---|---|
| HeadacheNervous system disorders | 0/55 | 3/52 |
| NauseaGastrointestinal disorders | 0/55 | 2/52 |
| PyrexiaGeneral disorders | 2/55 | 0/52 |
| VomitingGastrointestinal disorders | 0/55 | 1/52 |
| Limb injuryInjury, poisoning and procedural complications | 0/55 | 1/52 |
| Skin lacerationInjury, poisoning and procedural complications | 0/55 | 1/52 |
| DizzinessNervous system disorders | 0/55 | 1/52 |
| Abdominal pain upperGastrointestinal disorders | 1/55 | 0/52 |
| ChokingRespiratory, thoracic and mediastinal disorders | 1/55 | 0/52 |
| Age Continuous(Years) | Placebo | Dextromethorphan Hydrobromide | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.8 | 8.9 ± 1.6 | 8.9 ± 1.7 |
| Sex: Female, Male(Participants) | Placebo | Dextromethorphan Hydrobromide | Total |
|---|---|---|---|
| Female | 32 | 25 | 57 |
| Male | 23 | 27 | 50 |
The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 6 months after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan